NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
1. "Bonzyme" Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder.
2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability.
3. Exclusive “Bonpure” seven-step purification technology, high purity (up to 99%) and stability of production of NMNH powder
4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder
5. Provide one-stop product solution customization service
When applied to cultured cells, the NMNH is shown to be more efficient than NMN as it was able to “significantly increase NAD+ at a ten times lower concentration (5 µM) than that needed for NMN”. Moreover, NMNH shows to be more effective , as at 500 µM concentration, it achieved “an almost 10-fold increase in the NAD+ concentration, while NMN was only able to double NAD+ content in these cells, even at 1 mM concentration.”.
Interestingly, NMNH also appears to act quicker and has a longer-lasting effect compared to NMN. According to the authors, NMNH induces a “significant increase in NAD+ levels within 15 minutes”, and “NAD+ steadily increased for up to 6 hours and remained stable for 24 hours, while NMN reached its plateau after only 1 hour, most likely because the NMN recycling pathways to NAD+ had already become saturated.”.
The main methods of NMNH powder preparation include extraction, fermentation, fortification, biosynthesis and organic matter synthesis. Compared with other preparations, the whole enzyme becomes the mainstream method owing to the advantages of pollution free, high level of purity and
NADH is synthesized by the body and thus is not an essential nutrient. It does require the essential nutrient nicotinamide for its synthesis, and its role in energy production is certainly an essential one. In addition to its role in the mitochondrial electron transport chain, NADH is produced in the cytosol. The mitochondrial membrane is impermeable to NADH, and this permeability barrier effectively separates the cytoplasmic from the mitochondrial NADH pools. However, cytoplasmic NADH can be used for biologic energy production. This occurs when the malate-aspartate shuttle introduces reducing equivalents from NADH in the cytosol to the electron transport chain of the mitochondria. This shuttle mainly occurs in the liver and heart.
Nicotinamide adenine dinucleotide (NAD+ ) homeostasis is constantly compromised due to degradation by NAD+ -dependent enzymes. NAD+ replenishment by supplementation with the NAD+ precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) can alleviate this imbalance. However, NMN and NR are limited by their mild effect on the cellular NAD+ pool and the need of high doses. Here, we report a synthesis method of a reduced form of NMN (NMNH), and identify this molecule as a new NAD+ precursor for the first time. We show that NMNH increases NAD+ levels to a much higher extent and faster than NMN or NR, and that it is metabolized through a different, NRK and NAMPT-independent, pathway. We also demonstrate that NMNH reduces damage and accelerates repair in renal tubular epithelial cells upon hypoxia/reoxygenation injury. Finally, we find that NMNH administration in mice causes a rapid and sustained NAD+ surge in whole blood, which is accompanied by increased NAD+ levels in liver, kidney, muscle, brain, brown adipose tissue, and heart, but not in white adipose tissue. Together, our data highlight NMNH as a new NAD+ precursor with therapeutic potential for acute kidney injury, confirm the existence of a novel pathway for the recycling of reduced NAD+ precursors and establish NMNH as a member of the new family of reduced NAD+ precursors.
First, inspect the factory. After some screening, NMNH companies that directly face consumers pay more attention to brand building. Therefore, for a good brand, quality is the most important thing, and the first thing to control the quality of raw materials is to inspect the factory. Bontac company actually manufacturing NMNH powder of high quality with the caterias of SGS. Secondly, the purity is tested. Purity is one of the most important parameters of NMN powder. If high purity NMNH cannot be guaranteed, the remaining substances are likely to exceed the relevant standards. As the attached certificates demonstrates that the NMNH powder produced by Bontac reach the purity of 99%. Finally, a professional test spectrum is needed to prove it. Common methods for determining the structure of an organic compound include Nuclear Magnetic Resonance Spectroscopy (NMR) and high-resolution mass spectrometry (HRMS). Usually through the analysis of these two spectra, the structure of the compound can be preliminarily determined.
Bontac in Boao Health Food Science Conference & Expo(FHE) From 22 to 25 February 2023, the Boao Health Food Science Conference and Expo was successfully held at the permanent venue of the Boao Forum for Asia in Hainan, China. This international conference build an international platform for exchange and cooperation among government, academia, industry, and industry, academia and research, which aims to promote the development of the health food industry through the exchange of scientific information at home and abroad. Bontac performace in FHE The conference gathered several prominent scientists including 10 academicians, over 200 experts and scholars, and invited many popular food enterprises likely Nestle, Pepsi from the United States, Europe, Japan, Australia, New Zealand and other countries. More importantly, exhibition featured a number of high-tech companies that focus on high-tech development of the production of nutritious and healthy food products. As one of the high-tech companies attending the exhibition, Bontac, which has obtained over 160 international patents and is committed to the design of new biosynthetic pathways to explore and mass-produce natural products for food ingredients, was invited to attend the conference and companies vital stake holders to deliver academic views on the technological innovation and healthy development of the food industry. Figure 1: Xinhua Officical Record for Bontac in FHE Bontac Products in FHE Expo Bontac main products starring NMN, rare ginsenosides, NAD, NADH and NADPH were all present at booth C34 in FHE Expo. And that booth C34 attracted lots of exhibitors to consult who communicated with each other upon appearance owing to the obvious striking advantages likely Bontac manufacture technology of whole coenzyme, sustainable supply chain, complete quality system and environment-protection and energy-saving preparation. What’s more, the academician of the Chinese Academy of Engineering and Chairman of FHE, Chen Junshi also visited Bontac booth and highly commend on the Bontac performance and demonstration. Figure 2: Chen Visited Bontac Booth in FHE Bontac recognizes the importance of the upstream of raw material side in biotechnology as the key to product innovation. On the other hand, with the increasingly demand for high-quality food, synthetic biotechnology stands on the point of the potential to provide consumers with greener and healthier food ingredients. Therefore, as far as Bontac is concerned, developing and shaping innovative technology ownership supports to effectively solving the problem of insufficient plant and animal extracts, reducing the environmental burden, and contributing to carbon neutrality and human sustainable development. At present, Bontac has already launched industrialized stevioside and rare ginsenoside which can be utilized in the field of health food. In future, Bontac will set up more product lines for more raw materials with higher purity and better quality as health food ingredients. Bontac honor time in FHE It was great honor for Bontac to win innovative product enterprise award, which identified Bontac long-term commitment to the exploration and innovation of synthetic biology and health technology products. Furthermore, it also reflects the R&D capability and innovation ability of Bontac in the field of synthetic biology, which will surely inspire Bontac to invest more actively in R&D and innovation. Figure 3: Bontac Award in FHE Dr. Qi Zhang, Founder and Chief Scientist of Bontac, delivered a speech entitled Efficient Green Biosynthesis of Ginsenosides, NMN and other Natural Products at the Innovative Technology and Innovative Manufacturing forum, explaining the green safety, wide applicability and innovative value of synthetic biotechnology from the theoretical source. Figure 4: Dr. Zhang in FHE Dr. Zhang demonstrated that Bontac holds up on the technology of biosynthesis of coenzyme preparation for natural products such as ginsenosides, especially rare ginsenosides Rh2 and Rg3. The advantages focuses on breaking through the limitations of raw materials, facilitating industrial scale-up, shorting reaction cycle, milder conditions, green environment and energy saving, but maintains the point of sustainable development. On the 23rd, a roundtable discussion on the "Technology and Investment in the Food Industry". Shu Shangke, Chairman of Bontac, attended the forum on the theme of Technology and Investment in the Food Industry and said that synthetic biotechnology is bringing about a revolution in the food and pharmaceutical fields, pushing these fields to iterate and upgrade. In the food industry, having strong R&D strength, leading technology and abundant patents are important factors for a company to have core competitiveness and investment value. Figure 5: Shu in FHE
In today's health and anti-aging fields, NMN (nicotinamide mononucleotide) has attracted a lot of attention. As an important cellular coenzyme, NMN plays a key role in maintaining cell health and delaying the aging process. However, it is not easy to find a manufacturer that can provide high-quality NMN. Here, we will introduce BONTAC, a High Quality NMN Manufacturer Factory. BONTAC: Focus on the production of NMN BONTAC is a company specializing in the development and production of biochemical products, including NMN. They have advanced production equipment and technology, as well as a team of experienced scientists and engineers, dedicated to providing high-quality NMN. Their R&D team continues to explore and innovate to ensure that their NMN products are always at the forefront of the industry. High quality NMN BONTAC's NMN products are known for their high purity and stability. Their NMN is produced in a strictly controlled environment to ensure its quality and purity. In addition, they undergo rigorous quality testing on each batch of products to ensure it meets the highest quality standards. Their quality control team strictly monitors every step of production, from the selection of raw materials to the packaging of the final product, to ensure the excellent quality of the products. Customer first BONTAC not only provides high-quality products, but also provides excellent customer service. Their team is always customer-oriented and provides customized solutions to meet the needs of different customers. Whether you are a large enterprise or a small research institution, BONTAC can provide the services you need. Their customer service team is always ready to provide customers with professional consultation and support to ensure that their needs are met. Conclusion BONTAC is a High Quality NMN Manufacturer Factory, the high quality NMN and excellent customer service they provide make them stand out in the industry. If you are looking for a reliable NMN supplier, BONTAC is undoubtedly an option worth considering. Their expertise, strict quality control and excellent customer service have earned them an excellent reputation in the NMN manufacturing field. Whether you are a consumer or a researcher, when you choose BONTAC, you will receive the highest quality NMN products and services. Let us look forward to BONTAC bringing more innovations and breakthroughs in the future, opening up more possibilities for our health and longevity.
Introduction Acute promyelocytic leukemia (APL), the M3 type of acute myeloid leukemia (AML), typically relies on all-trans retinoic acid (ATRA) as its primary treatment. While APL patients treated with ATRA exhibit a high bone marrow complete remission rate, ATRA resistance severely limits its efficacy and contributes to a poor prognosis. Recent research underscores the potential of 20(S)-ginsenoside Rh2 (GRh2) as a lactylation-modified METTL3 inhibitor to ameliorate ATRA-resistance in APL, providing a new direction for the development of novel drugs for APL. About APL APL, constituting 10-15% of all AML cases, is characterized by abnormal promyelocyte proliferation, with associated complications such as bone marrow dysfunction and anemia. In the 1960s and 1970s, APL is a medical emergency with high mortality rate, and API-related death is often attributed to bleeding due to coagulation disorders. With the invention and evolution of new drugs, the prognosis of APL patients has been greatly improved. The 10-year survival rate for APL patients today is estimated to be about 80-90%. Differentiation-inducing agent, such as ATRA, is an essential part for the treatment of APL. Leukemic stem cells (LSCs) and ATRA-resistant APL cells primary contributors to leukemia recurrence post-remission. Addressing these residual issues is of great importance in the pursuit of improved treatment outcomes. The association between METTL3 and ATRA-resistance in APL METTL3 is a promising therapeutic target for ATRA resistant APL. Upregulation of METTL3, which is driven by lactylation modifications, promotes ATRA-resistance in APL, as indicated by the increased number of CD45+ leukemia cells and Giemsa positive cells in the METTL3-OE group. The suppressive impact of GRh2 upon ATRA-resistance in APL In vitro, GRh2 increases histone acetylation levels and considerably inhibits the lactylation level in ATRA-resistant APL cells, and promotes the apoptosis of ATRA-resistance LSCs, acting as a histone lactylation inhibitor. In addition to repressing the enzyme activity of METTL3, GRh2 dose-dependently inhibits the expression levels of METTL3 and MEETL3 and its downstream reading protein YTHDF2, YTHDF1 and YTHDC1 in ATRA-resistant APL cells. Molecular docking analysis shows that GRh2 can directly bind with METTL3. In vivo, GRh2 suppresses METTL3 expression, tumor weight and volume, yet enhances the sensitivity to ATRA differentiation therapy in mice with ATRA-resistant APL xenograft tumors. Moreover, GRh2 treatment considerably elevates the survival of ATRA-resistant APL xenograft mice. Conclusion Mechanically, GRh2 can reduce ATRA resistance in APL by repressing lactylation-driven METTL3. Further exploration of this interaction could lead to the development of more effective and personalized treatment strategies for APL patients, ultimately improving their prognosis and quality of life. Reference Cheng S, Chen L, Ying J, et al. 20(S)-ginsenoside Rh2 ameliorates ATRA resistance in APL by modulating lactylation-driven METTL3. J Ginseng Res. 2024;48(3):298-309. doi:10.1016/j.jgr.2023.12.003 BONTAC Ginsenosides BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of rare ginsenosides Rh2/Rg3, with pure raw materials, higher conversion rate and higher content (up to 99%). One-stop service for customized product solution is available in BONTAC. With unique Bonzyme enzymatic synthesis technology, both S-type and R-type isomers can be accurately synthesized here, with stronger activity and precise targeting action. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be responsible for any claims, damages, losses, expenses, or costs arising directly or indirectly from your reliance on the information and material on this website.